Navigation Links
A new drug target in atherosclerosis: The anaphylatoxin C5a
Date:1/4/2011

For decades, doctors have looked at fitness levels, weight, and overall health risk factors for heart disease and stroke. Now, they may soon add a new risk factor to the list: activation of the complement system. The complement system is usually implicated in immune responses, but now there's a role for it in cardiovascular disease. In a new research report appearing in the January 2011 print issue of the FASEB Journal (http://www.fasebj.org), scientists from Europe and the United States show that anaphylatoxin C5a, a protein released when complement is activated, contributes to atherosclerotic disease. C5a causes plaques to break free from where they would be anchored to ultimately cause blockages elsewhere in the body. This new discovery not only shows that C5a is a new marker for identifying risk for heart attack and stroke, but it also establishes C5a as a new therapeutic target for preventing these problems.

"Given the huge impact of cardiovascular disease in general, and atherosclerosis in particular, on public health, we feel that unraveling mechanisms involved in the development and progression of the disease are of utmost importance," said Johann Wojta, Ph.D., a researcher involved in the work from the University of Vienna in Austria. "Our findings have identified a particular component possibly involved in the development of atherosclerosis as a target for future therapies."

To make this discovery, Wojta and colleagues treated white blood cells with the C5a. In turn, these cells responded with the production of specific enzymes capable of dissolving the inner wall of atherosclerotic plaques in coronary or brain vessels. This causes the plaques to rupture, break free from where they are anchored, and ultimately create a blockage of the vessels, leading to the development of more serious problems such as heart attacks or strokes. The researchers also showed that C5a was present in blood vessels of patients with myocardial infarction, but not in cardiac patients without infarct. This suggests that inhibiting C5a might provide a therapeutic tool in the prevention or treatment of atherosclerosis, as well as other diseases with immune system participation such as arthritis.

"Up to now, anaphylatoxin C5a has been mainly implicated in immunologic diseases such as asthma, rheumatoid arthritis or lupus," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal. "But now, this study shows that C5a, a product of an activated complement system may be responsible for the devastating effects of atherosclerosis."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. CSHL scientists identify elusive neuronal targets of deep brain stimulation
2. Delivering drugs to the brain: New research into targeted treatment of Alzheimers
3. Biodiversity targets for the future
4. Researchers discover potential genetic target for heart disease
5. TB-drugome provides new targets for anti-tuberculosis drug discovery
6. UCLA researchers discover a potential target for therapy for patients with a deadly prostate cancer
7. UNC team discovers promising target for new pancreatic cancer treatments
8. Rictor protein offers scientists a new molecular target for cancer therapies
9. Putting a bulls-eye on the flu: Paper details influenzas structure for future drug targeting
10. Link between 2 forms of ALS suggests drug target
11. New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology: